Press Releases

Date Title and Summary View
Toggle Summary MediWound Reports Third Quarter 2022 Financial Results and Provides Company Update
$30.5 million in gross proceeds raised; operating cash runway through 2025 NexoBrid PDUFA date of January 1, 2023 ; Upon approval,   NexoBrid expected to generate meaningful revenues Company f ocus ed on the billion-dollar market opportunity with EscharEx Phase 3 clinical study to begin in
View HTML
Toggle Summary MediWound’s EscharEx Featured in Paper as a Potential Paradigm Shift Towards Non-Surgical Wound Bed Preparation in DFUs
Paper published in the November 2022 issue of Podiatry Management ( Robert J. Snyder , DPM, Cyaandi Dove, DPM, and Vickie Driver , DPM, MS) YAVNE, Israel , Nov. 09, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation
View HTML
Toggle Summary MediWound to Report Third Quarter 2022 Financial Results
Conference Call and Webcast Scheduled for Tuesday, November 15, 2022 at 8:30 am Eastern Time YAVNE, Israel , Nov. 03, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and
View HTML
Toggle Summary MediWound Announces Formation of Strategic Advisory Board
Esteemed group of industry leaders to contribute expertise and experience to MediWound’s strategic and operational activities YAVNE, Israel , Oct. 25, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic
View HTML
Toggle Summary MediWound's EscharEx® Featured in Oral and Poster Presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2022
EscharEx’s promising results from the completed Phase 2 trials were highlighted YAVNE, Israel , Oct. 18, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today
View HTML
Toggle Summary MediWound Announces Closing of the Concurrent Registered Direct and Private Placement Offerings
Gross Proceeds of $30.5 Million Raised YAVNE, Israel , Oct. 07, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced the closing of its previously
View HTML
Toggle Summary MediWound Announces Concurrent Registered Direct and Private Placement Offerings Priced At-the-Market of Approximately $30 Million
YAVNE, Israel , Sept. 22, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) (the “Company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that it has entered into a definitive securities
View HTML
Toggle Summary EMA Accepts MediWound’s Application for Extended Indication for NexoBrid to Treat Pediatric Patients with Severe Thermal Burns
Upon approval, NexoBrid will serve as a safe and effective non-surgical treatment option in the EU for children with severe burns YAVNE, Israel , Sept. 20, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) (the “Company”), a fully integrated biopharmaceutical company focused on next-generation
View HTML
Toggle Summary MediWound’s NexoBrid® Highlighted in 45 Posters and Presentations at the 19th European Burns Association Congress
YAVNE, Israel, Sept. 12, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced its successful and meaningful presence at the recently
View HTML
Toggle Summary MediWound Reports Second Quarter 2022 Financial Results and Provides Company Updates
Positive Results in Two Phase 2 Trial s of EscharEx FDA Assigned PDUFA Target Date of January 1 ,   202 3   for NexoBrid BLA Enhance d the Board and L eadership T eam Conference C all B egins T oday at 8:30 AM   Eastern Time YAVNE, Israel , Aug. 09, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd.
View HTML